103.49MMarket Cap-1.55P/E (TTM)
1.6500High1.5200Low143.13KVolume1.6000Open1.6000Pre Close224.39KTurnover0.29%Turnover RatioLossP/E (Static)65.50MShares3.790052wk High1.19P/B76.89MFloat Cap1.080052wk Low--Dividend TTM48.66MShs Float3071.9974Historical High--Div YieldTTM8.13%Amplitude0.7600Historical Low1.5670Avg Price1Lot Size
Regulus Therapeutics Stock Forum
📊⚡️📊
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vanguard loaded
Regulus Therapeutics Inc., a biopharmaceutical company listed on Nasdaq under the ticker symbol RGLS, has recently announced positive topline results from the third cohort of patients in its Phase 1b Multiple-Ascending Dose (MAD) clinical trial of RGLS8429. This investigational drug is being developed for the treatment of ...
No comment yet